Raymond James Financial, Inc.
RJFRaymond James Financial, Inc. is strength at full price. The numbers are improving — and a P/BV at the 88th percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 88th percentile of its own range you are paying full price for it.
The price is topping out (1 weeks in) while the P/BV sits at the 88th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +10.2% year on year, with the the net margin at 14.0%. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Raymond James Financial, Inc. trades at $179, losing momentum at the top and 1 weeks into that stage. That is +12.7% against its own 200-day average. It sits at 100% of a 52-week range of $141 to $179. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 6 straight weeks.
Today the stock is losing momentum at the top — week 1 of stage 3. At $179 it trades +12.7% versus its 200-day average and sits at 100% of its 52-week range ($141–$179).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +435% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 6 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each $1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.
Raymond James Financial, Inc. trades at 2.8× P/BV, at the pricey end of its own range (88th percentile). Its long-run median P/BV is 2.5×, measured across 5.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/BV of 2.8× is at the pricey end of its own range (88th percentile), against a long-run median of 2.5× measured over 5.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year book value grew while the price moved +9.5% — the price ran ahead of the book, pushing the multiple up its own range.
The price move, decomposed: over 5y, of the +14.9%/yr price move, ~+11.2%/yr came from book-value growth and ~+3.7 pp from the multiple (expanding). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the book-value line underneath it, not the multiple.
Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Raymond James Financial, Inc. reads as topping out on its fundamental arc. Topping out — profit and EPS growth have decelerated hard (profit growth +22.5% at its peak → −1.8% latest) while ROE still reads 17.0%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +9.7% | +8.5% | — | — |
| Profit | +2.9% | +12.2% | — | — |
| EPS | +6.2% | +13.8% | — | — |
| Stock price | +9.5% | +18.3% | +14.9% | +17.0% |
4-Factor Sector Score
59.0/100 — rank 2 of 29 in Asset Management · 60% evidence confidence
Raymond James Financial, Inc. scores 59.0 out of 100 against the 29 companies it is compared with in Asset Management, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 21.3 + 15.3 + 11 + 11.4 = 59. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.
Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fees from its businesses.
Raymond James Financial, Inc. reported $3.9 B of income in the Mar 26 quarter, +13.5% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 9.6% a year. The last full year, FY25, came in at $14.1 B. The last four reported quarters add to $14.7 B.
FY25 revenue came in at $14.1 B (+9.7% on the year), capping 4 years at 9.6% compound. The latest quarter (Mar 26) printed $3.9 B, +13.5% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +8.0% growth against the decade's 9.6% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +8.0% over the last 4 quarters against +10.3%/yr over the last 8 — stabilising; TTM profit −1.8% vs +9.6%/yr — rolling over.
Net margin Net margin — what the bank keeps of every $100 of revenue after every cost, provision and tax. With big fee businesses in the mix, it is the cleanest margin we can read for this bank.
Raymond James Financial, Inc.'s net margin is 14.0% in the Mar 26 quarter, −0.4 percentage points against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 13.7% to 16.1%. The current quarter sits inside that band.
The latest quarter's net margin is 14.0%, −0.4 pp against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 13.7%–16.1%.
Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Raymond James Financial, Inc. earned $0.5 B of net profit in the Mar 26 quarter, +10.2% year on year. Full-year FY25 profit was $2.1 B. The 4-year compound rate is 11.1%. That is 14.0% of the quarter's revenue. The same quarter a year earlier earned $0.5 B.
Mar 26 profit was $0.5 B, +10.2% year on year. On the full year, FY25 printed $2.1 B (+2.9%), and the 4-year compound rate is 11.1%.
Why profit moved: revenue contributed +13.5% and the margin −0.4 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit −1.7% vs revenue +8.0%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.
Loan-book quality history is not available for Raymond James Financial, Inc., so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.
We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.
Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.
The loan book We read the loan book through revenue — when the book and the businesses grow, revenue grows with them. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.
Raymond James Financial, Inc.'s revenue grew +9.7% in FY25 to $14.1 B, so the book is growing. The latest quarter ran +13.5% year on year. The net margin on that income is 14.0%, −0.4 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.
FY25 revenue was $14.1 B, +9.7% on the year, and the latest quarter ran +13.5% year on year. The net margin on that revenue is 14.0% this quarter (−0.4 pp YoY) — growth with a narrowing margin on it.
The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — with quarterly loan-quality numbers missing here, revenue growth and margin are the two we watch.
Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.
Raymond James Financial, Inc. earns a return on equity of 17% in FY25. Its trough over the ladder below was 16% in FY22. On the asset side every $100 of the balance sheet earned about $2.45, which is the return before leverage is applied.
FY25 ROE came in at 17%, recovered from a FY22 trough of 16%. On assets, the latest reading is about 2.45% — every $100 the bank deploys earns roughly $2.45 a year. That clears the bar a bank must beat for its book value to compound.
Why ROE moved: profit compounded 11.1% a year over 4 years while the equity base grew more slowly — earnings recovering faster than book value builds is what lifts ROE off a trough.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Raymond James Financial, Inc. paid $2.08 per share over the last four reported quarters, up 8.0% on a year ago. The most recent declaration was $0.54 for Mar 26. Against the current price of $179 that is a trailing yield of 1.16%, measured on dividends already paid rather than on a forecast.
Raymond James Financial, Inc. paid $2.08 per share across the last four reported quarters, most recently $0.54 for Mar 26. That is up 8.0% against the same quarter a year earlier. Against the current price of $179 the trailing twelve months work out to 1.16% — trailing dividends measured against today's price, not a forward estimate.
Debt
For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.
A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
5.6% of Raymond James Financial, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 6.0 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 5.6% of the float is sold short, and at typical trading volumes it would take about 6.0 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Raymond James Financial, Inc.: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.
The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Victory Capital Holdings, Inc.VCTR | 66.2/100Favorable setup76% evidence | LEADER | 24.7/35 Income 64.1% · PAT 29.1% 71% evidence | 16.5/25 ROA 3.6% · ROE 6.4% · GNPA — 68% evidence | 7.9/20 P/BV 2.29× · P/BV÷ROE 0.36 70% evidence | 17.1/20 RS sector 21% · RS bench 25.6% · 1Y 45.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 16.5 + 7.9 + 17.1 = 66.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Raymond James Financial, Inc.this pageRJF | 59.0/100Mixed-positive evidence60% evidence | BREAKING OUT | 21.3/35 Income — · PAT — 26% evidence | 15.3/25 ROA 1.4% · ROE 9.7% · GNPA — 68% evidence | 11.0/20 P/BV 2.24× · P/BV÷ROE 0.23 70% evidence | 11.4/20 RS sector -3.3% · RS bench 0% · 1Y 8.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 15.3 + 11 + 11.4 = 59 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Affiliated Managers Group, Inc.AMG | 57.8/100Mixed-positive evidence60% evidence | BREAKING OUT | 20.1/35 Income — · PAT — 26% evidence | 14.6/25 ROA 1.6% · ROE 6.1% · GNPA — 68% evidence | 6.9/20 P/BV 2.94× · P/BV÷ROE 0.48 70% evidence | 16.2/20 RS sector 14.9% · RS bench 19.4% · 1Y 81.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 14.6 + 6.9 + 16.2 = 57.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4SEI Investments CompanySEIC | 56.7/100Mixed-positive evidence60% evidence | BREAKING OUT | 17.9/35 Income — · PAT — 26% evidence | 17.6/25 ROA 5.2% · ROE 7.7% · GNPA — 68% evidence | 5.9/20 P/BV 4.21× · P/BV÷ROE 0.55 70% evidence | 15.3/20 RS sector 5.7% · RS bench 9.5% · 1Y 19.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 17.6 + 5.9 + 15.3 = 56.7 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 5BlackRock, Inc.BLK | 53.3/100Mixed-positive evidence80% evidence | BASING | 22.9/35 Income 26.5% · PAT 9.2% 81% evidence | 16.4/25 ROA 2.5% · ROE 7.9% · GNPA — 68% evidence | 8.4/20 P/BV 2.64× · P/BV÷ROE 0.33 70% evidence | 5.6/20 RS sector -8.3% · RS bench -5.1% · 1Y 0.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 16.4 + 8.4 + 5.6 = 53.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8.3% and the one-year return is 0.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 6Blackstone Inc.BX | 50.6/100Mixed-positive evidence60% evidence | TURNING | 20.8/35 Income — · PAT — 26% evidence | 18.1/25 ROA 5% · ROE 10.8% · GNPA — 68% evidence | 4.4/20 P/BV 9.7× · P/BV÷ROE 0.9 70% evidence | 7.3/20 RS sector -14.2% · RS bench -11.8% · 1Y -18.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 18.1 + 4.4 + 7.3 = 50.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 7State Street CorporationSTT | 50.3/100Mixed-positive evidence60% evidence | LEADER | 17.7/35 Income — · PAT — 26% evidence | 9.3/25 ROA 0.3% · ROE 3.9% · GNPA — 68% evidence | 7.1/20 P/BV 1.66× · P/BV÷ROE 0.43 70% evidence | 16.2/20 RS sector 18.2% · RS bench 23% · 1Y 66.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 9.3 + 7.1 + 16.2 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Janus Henderson Group plcJHG | 50.0/100Mixed-positive evidence70% evidence | 19.9/35 Income 24.5% · PAT 100% 71% evidence | 11.1/25 ROA 1.2% · ROE 1.9% · GNPA — 68% evidence | 5.5/20 P/BV 1.53× · P/BV÷ROE 0.81 70% evidence | 13.5/20 RS sector 6.2% · RS bench 0.6% · 1Y 28.9%0 of 7 weeks ahead to 2026-07-02 70% evidence | |
| Exact sum: 19.9 + 11.1 + 5.5 + 13.5 = 50 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Invesco Ltd.IVZ | 49.8/100Mixed-negative evidence60% evidence | BREAKING OUT | 19.1/35 Income — · PAT — 26% evidence | 10.4/25 ROA 1% · ROE 2.4% · GNPA — 68% evidence | 7.3/20 P/BV 0.94× · P/BV÷ROE 0.39 70% evidence | 13.0/20 RS sector 8.4% · RS bench 12.4% · 1Y 54.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 10.4 + 7.3 + 13 = 49.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10T. Rowe Price Group, Inc.TROW | 49.7/100Mixed-negative evidence60% evidence | BREAKING OUT | 17.3/35 Income — · PAT — 26% evidence | 15.7/25 ROA 2.8% · ROE 6.1% · GNPA — 68% evidence | 7.5/20 P/BV 2.21× · P/BV÷ROE 0.36 70% evidence | 9.2/20 RS sector -2.8% · RS bench 0.6% · 1Y 10.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 15.7 + 7.5 + 9.2 = 49.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Ares Management CorporationARES | 48.7/100Mixed-negative evidence60% evidence | BREAKING OUT | 20.7/35 Income — · PAT — 26% evidence | 14.1/25 ROA 1.5% · ROE 7.1% · GNPA — 68% evidence | 4.8/20 P/BV 6.11× · P/BV÷ROE 0.86 70% evidence | 9.1/20 RS sector -11.7% · RS bench -9.3% · 1Y -24.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 14.1 + 4.8 + 9.1 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12StepStone Group Inc.STEP | 46.6/100Thin evidence · provisional55% evidence | BASING | 23.2/35 Income 69.7% · PAT — 45% evidence | 13.4/25 ROA 6.9% · ROE 0.5% · GNPA — 68% evidence | 9.8/20 P/BV -9.31× · P/BV÷ROE — 10% evidence | 0.2/20 RS sector -24.7% · RS bench -22.5% · 1Y -16.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 23.2 + 13.4 + 9.8 + 0.2 = 46.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Franklin Resources, Inc.BEN | 46.5/100Mixed-negative evidence60% evidence | LEADER | 17.5/35 Income — · PAT — 26% evidence | 8.8/25 ROA 0.4% · ROE 1.8% · GNPA — 68% evidence | 5.8/20 P/BV 1.44× · P/BV÷ROE 0.8 70% evidence | 14.4/20 RS sector 16% · RS bench 20.5% · 1Y 43.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 8.8 + 5.8 + 14.4 = 46.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Hamilton Lane IncorporatedHLNE | 45.5/100Mixed-negative evidence76% evidence | TURNING | 15.1/35 Income 6.6% · PAT 24% 71% evidence | 17.8/25 ROA 3.6% · ROE 9.6% · GNPA — 68% evidence | 6.3/20 P/BV 4.75× · P/BV÷ROE 0.49 70% evidence | 6.3/20 RS sector -22.9% · RS bench -21% · 1Y -34.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 17.8 + 6.3 + 6.3 = 45.5 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 15Corebridge Financial, Inc.CRBG | 44.7/100Thin evidence · provisional55% evidence | BREAKING OUT | 19.1/35 Income 14.6% · PAT -71.3% 45% evidence | 5.2/25 ROA 0% · ROE -0.5% · GNPA — 68% evidence | 9.8/20 P/BV 1.01× · P/BV÷ROE — 10% evidence | 10.6/20 RS sector -7.3% · RS bench -4.4% · 1Y -5.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 5.2 + 9.8 + 10.6 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Principal Financial Group, Inc.PFG | 43.3/100Mixed-negative evidence60% evidence | BREAKING OUT | 15.9/35 Income — · PAT — 26% evidence | 7.5/25 ROA 0.1% · ROE 3.6% · GNPA — 68% evidence | 6.4/20 P/BV 1.91× · P/BV÷ROE 0.53 70% evidence | 13.5/20 RS sector 7.3% · RS bench 11.5% · 1Y 50.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 7.5 + 6.4 + 13.5 = 43.3 · Decision use: Price leads the evidence: RS versus the benchmark is 11.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 17Blue Owl Capital Inc.OWL | 42.6/100Mixed-negative evidence60% evidence | TURNING | 19.5/35 Income — · PAT — 26% evidence | 12.1/25 ROA 1.6% · ROE 1.9% · GNPA — 68% evidence | 4.5/20 P/BV 2.94× · P/BV÷ROE 1.55 70% evidence | 6.5/20 RS sector -22.2% · RS bench -20.4% · 1Y -41.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 12.1 + 4.5 + 6.5 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Brookfield Asset Management Ltd.BAM | 41.6/100Mixed-negative evidence76% evidence | BASING | 16.2/35 Income 21.5% · PAT 10.5% 71% evidence | 15.5/25 ROA 3.3% · ROE 5.3% · GNPA — 68% evidence | 3.4/20 P/BV 9.38× · P/BV÷ROE 1.77 70% evidence | 6.5/20 RS sector -11.6% · RS bench -8.8% · 1Y -15.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 15.5 + 3.4 + 6.5 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Equitable Holdings, Inc.EQH | 37.7/100Mixed-negative evidence76% evidence | BREAKING OUT | 12.0/35 Income -23.4% · PAT -126% 71% evidence | 12.7/25 ROA 0.3% · ROE 24.1% · GNPA — 68% evidence | 3.4/20 P/BV 38.27× · P/BV÷ROE 1.59 70% evidence | 9.6/20 RS sector -8.4% · RS bench -5.6% · 1Y -7.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 12.7 + 3.4 + 9.6 = 37.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20TPG Inc.TPG | 36.5/100Mixed-negative evidence64% evidence | TURNING | 16.6/35 Income 11.5% · PAT 100% 71% evidence | 4.4/25 ROA -0.8% · ROE -3.4% · GNPA — 68% evidence | 9.4/20 P/BV 5.73× · P/BV÷ROE — 10% evidence | 6.1/20 RS sector -17.4% · RS bench -15.2% · 1Y -20.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 4.4 + 9.4 + 6.1 = 36.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21KKR & Co. Inc.KKR | 35.7/100Mixed-negative evidence60% evidence | TURNING | 16.8/35 Income — · PAT — 26% evidence | 7.9/25 ROA 0.2% · ROE 2.1% · GNPA — 68% evidence | 4.9/20 P/BV 2.7× · P/BV÷ROE 1.28 70% evidence | 6.1/20 RS sector -16.2% · RS bench -13.9% · 1Y -24.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 7.9 + 4.9 + 6.1 = 35.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Brookfield CorporationBN | 35.4/100Mixed-negative evidence76% evidence | ASLEEP | 20.1/35 Income -6.7% · PAT 100% 71% evidence | 8.6/25 ROA 0.7% · ROE 0.5% · GNPA — 68% evidence | 3.7/20 P/BV 2.95× · P/BV÷ROE 5.9 70% evidence | 3.0/20 RS sector -13.3% · RS bench -10.3% · 1Y 3.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 8.6 + 3.7 + 3 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Apollo Global Management, Inc.APO | 31.8/100Adverse evidence64% evidence | ASLEEP | 12.3/35 Income 28.2% · PAT -45% 71% evidence | 5.2/25 ROA -0.5% · ROE -3.9% · GNPA — 68% evidence | 9.7/20 P/BV 3.22× · P/BV÷ROE — 10% evidence | 4.6/20 RS sector -9.9% · RS bench -7% · 1Y -6.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 12.3 + 5.2 + 9.7 + 4.6 = 31.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Blue Owl Capital CorporationOBDC | 27.0/100Adverse evidence62% evidence | BASING | 9.4/35 Income -11% · PAT -50.5% 55% evidence | 10.1/25 ROA — · ROE 0.5% · GNPA — 34% evidence | 4.7/20 P/BV 0.77× · P/BV÷ROE 1.53 70% evidence | 2.8/20 RS sector -19.5% · RS bench -16.9% · 1Y -21%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 10.1 + 4.7 + 2.8 = 27 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25The Carlyle Group Inc.CG | 25.3/100Adverse evidence64% evidence | BASING | 7.1/35 Income -28.9% · PAT -44% 71% evidence | 6.5/25 ROA 0.3% · ROE -2.1% · GNPA — 68% evidence | 9.6/20 P/BV 3.22× · P/BV÷ROE — 10% evidence | 2.1/20 RS sector -18.2% · RS bench -15.9% · 1Y -18.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 7.1 + 6.5 + 9.6 + 2.1 = 25.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Pershing Square Inc.PS | 56.4/100Thin evidence · provisional42% evidence | ASLEEP | 28.6/35 Income 68.8% · PAT 100% 71% evidence | 7.8/25 ROA 1% · ROE -35.8% · GNPA — 68% evidence | 10.0/20 P/BV — · P/BV÷ROE — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 2 weeks ahead 0% evidence |
| Exact sum: 28.6 + 7.8 + 10 + 10 = 56.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Ameriprise Financial, Inc.AMP | 54.8/100Thin evidence · provisional46% evidence | BREAKING OUT | 16.6/35 Income — · PAT — 10% evidence | 16.4/25 ROA — · ROE 17.9% · GNPA — 34% evidence | 7.1/20 P/BV 6.48× · P/BV÷ROE 0.36 70% evidence | 14.7/20 RS sector -0.2% · RS bench 3.2% · 1Y 9.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 16.4 + 7.1 + 14.7 = 54.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Northern Trust CorporationNTRS | 51.9/100Thin evidence · provisional46% evidence | LEADER | 18.4/35 Income — · PAT — 10% evidence | 12.5/25 ROA — · ROE 6% · GNPA — 34% evidence | 8.6/20 P/BV 1.99× · P/BV÷ROE 0.33 70% evidence | 12.4/20 RS sector 7% · RS bench 11.2% · 1Y 45.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 12.5 + 8.6 + 12.4 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Ares Capital CorporationARCC | 38.0/100Thin evidence · provisional46% evidence | BASING | 16.5/35 Income — · PAT — 10% evidence | 10.6/25 ROA — · ROE 1.2% · GNPA — 34% evidence | 6.0/20 P/BV 0.96× · P/BV÷ROE 0.8 70% evidence | 4.9/20 RS sector -13.5% · RS bench -10.6% · 1Y -12.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 10.6 + 6 + 4.9 = 38 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Raymond James Financial, Inc.'s stock price today?
Raymond James Financial, Inc. trades at $179, +9.5% over the past year. The company is valued at $34.0 B. The stock sits at 100% of its 52-week range of $141–$179, +12.7% versus its 200-day average. On the tape, the price is topping out, 1 weeks in. — as of 5 August 2026.
What were Raymond James Financial, Inc.'s latest quarterly results?
Raymond James Financial, Inc. reported total income of $3.9 B and net profit of $0.5 B for the Mar 26 quarter. Income rose 13.5% and profit rose 10.2% year on year. Earnings per share were $2.72. The net margin was 14.0%, 0.4 pp lower than a year earlier. — as of 5 August 2026.
What is Raymond James Financial, Inc.'s revenue?
Raymond James Financial, Inc. reported revenue of $3.9 B in the Mar 26 quarter, +13.5% year on year. For the full FY25 fiscal year, revenue was $14.1 B (+9.7%). Over the last 4 years revenue compounded at 9.6% a year. — as of 5 August 2026.
What is Raymond James Financial, Inc.'s profit?
Raymond James Financial, Inc. earned $0.5 B of net profit in the Mar 26 quarter, +10.2% year on year. Full-year FY25 profit was $2.1 B. The net margin ran 14.0% in the latest quarter. — as of 5 August 2026.
What is Raymond James Financial, Inc.'s market cap?
Raymond James Financial, Inc.'s market capitalisation is $34.0 B at a stock price of $179. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Raymond James Financial, Inc.'s P/BV ratio?
Raymond James Financial, Inc. trades at a P/BV of 2.8×, at the 88th percentile of its own 5-year range, against a long-run median of 2.5×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Raymond James Financial, Inc. pay a dividend?
Yes — Raymond James Financial, Inc. declared $0.54 per share for Mar 26, and $2.08 per share across the last four reported quarters. The latest quarter is up 8.0% on the same quarter a year earlier. — as of 5 August 2026.
What is Raymond James Financial, Inc.'s dividend per share?
Raymond James Financial, Inc.'s most recently declared dividend is $0.54 per share for Mar 26, giving $2.08 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Raymond James Financial, Inc.'s dividend yield?
Raymond James Financial, Inc.'s trailing dividend yield is 1.16%: $2.08 declared per share across the last four reported quarters, against a share price of $179. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is Raymond James Financial, Inc. overvalued?
On its own history, Raymond James Financial, Inc. looks expensive against its own history: its P/BV of 2.8× sits at the 88th percentile of its 5-year range (long-run median 2.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is Raymond James Financial, Inc. growing?
Yes — Raymond James Financial, Inc. is growing: latest-quarter revenue +13.5% year on year, profit +10.2%, and the the net margin −0.4 pp at 14.0%. The 4-year compound rates are 9.6% (revenue) and 11.1% (profit). The earnings engine currently reads: improving — as of 5 August 2026.
How is Raymond James Financial, Inc. performing?
Raymond James Financial, Inc. is topping out, 1 weeks in. Its latest quarter's income rose 13.5% and profit rose 10.2% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Raymond James Financial, Inc. in?
Topping out — profit and EPS growth have decelerated hard (profit growth +22.5% at its peak → −1.8% latest) while ROE still reads 17.0%. The read comes from the last 12 quarters of growth (revenue growth +8.0% latest, profit growth −1.8% latest, eps growth +1.8% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Raymond James Financial, Inc. in an uptrend?
It is stalling — the price is topping out (week 1 of stage 3), trading +12.7% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Raymond James Financial, Inc. beating the market?
On recent form, yes — Raymond James Financial, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 6 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +435% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.
Will Raymond James Financial, Inc.'s stock price go up?
This page publishes no price forecast for Raymond James Financial, Inc. What it measures instead: the stock price is $179, the price is topping out 1 weeks in. Its P/BV of 2.8× sits at the 88th percentile of its own 5-year range. — as of 5 August 2026.
Is the market betting against Raymond James Financial, Inc.?
Somewhat — short interest is 5.6% of Raymond James Financial, Inc.'s tradable float, about 6.0 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Is Raymond James Financial, Inc.'s loan book healthy?
We do not hold quarterly loan-book quality numbers for Raymond James Financial, Inc., so this page says that plainly. The cleanest available reads are revenue growth (+9.7% in FY25) and the net margin on it (14.0%) — as of 5 August 2026.
Where is Raymond James Financial, Inc. in its business cycle?
Raymond James Financial, Inc.'s FY25 net margin was 15.1%, against a 5-year band of 13.7%–16.1%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 14.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Raymond James Financial, Inc. story?
The sharpest disagreement: the engine is strong, but at the 88th percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Raymond James Financial, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Raymond James Financial, Inc. is strength at full price. The numbers are improving — and a P/BV at the 88th percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.